ABSTRACT
Introduction There is a variety of ways in which the topic of male sexual dysfunction and the prostate could be tackled. However, the content of this chapter is largely restricted to analyzing the impact of drugs used for the treatment of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) on sexual function, and the potential utility of phosphodiesterase (PDE) 5 inhibitors in the treatment of LUTS. Covered elsewhere in this textbook is the impact of the urological surgeon. What is not covered is the role of the prostate in normal sexual function. What follows are some key messages rather than a comprehensive review of the literature. The focus is on the information that is most relevant to the management of BPH patients with and without comorbid sexual dysfunction (SD).
